


S/N 11/036,273



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Shubh D. SHARMA et al.	Examiner:	Unknown
Serial No.:	11/036,273	Group Art Unit:	Unknown
Filed:	January 14, 2005	Docket:	70025-US05-691
Title:	Metallopeptide Compositions for Treatment of Sexual Dysfunction		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b)(3) it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 50-3582 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

INFORMATION DISCLOSURE STATEMENT

Serial No :11/036,273

Page 2

Filing Date: January 14, 2005


Dkt: 70025-US05-691

Title: Metallopeptide Compositions for Treatment of Sexual Dysfunction

Respectfully submitted,

Date September 16, 2005

By


Stephen A. Slusher
Reg. No. 43,924


CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 16 day of September, 2005.

Brenda L. Guedagno
Name

Brenda L. Guedagno
Signature



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 				COMPLETE IF KNOWN		
				Application Number	11/036,273	
				Filing Date	January 14, 2005	
				First Named Inventor	SHARMA, Shubh D.	
				Group Art Unit	1639	
				Examiner Name	Unknown	
Sheet	1	of	4	Attorney Docket Number		70025-US05-691

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,027,711		Sharma, Shubh	02/22/2000	
		5,891,418		Sharma, Shubh	04/06/1999	
		5,576,290		M.E. Hadley	11/19/1996	
		6,051,555		M.E. Hadley	04/18/2000	
		5,674,839		V.J. Hraby, et al.	10/07/1997	
		5,714,576		V.J. Hraby, et al.	02/03/1998	
		6,579,968		Blood, et al.	06/17/2003	
		6,534,503		Dines, et al.	03/18/2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
			WO 02/064091		Sharma, et al.	08/22/02		
			WO 99/55679		Basu, et al.	11/04/99		
			WO 99/64002		Nargund, et al.	12/16/99		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\FORMS\PAT\1449a.pat.doc]

1. Unique citation designation number. 2. See attached Kinds of U.S. Patent Documents. 3. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10-31-99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN	
				Application Number	11/036,273
				Filing Date	January 14, 2005
				First Named Inventor	SHARMA, Shubh D.
				Group Art Unit	1639
				Examiner Name	Unknown
Sheet	2	of	4	Attorney Docket Number	70025-US05-691

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ²	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		6,472,398		Palucki, et al.	10/29/2002	
		6,458,790		Palucki, et al.	10/01/2002	
		6,410,548		Nargund, et al.	06/25/2002	
		6,376,509		Bakshi, et al.	04/23/2002	
		6,350,760		Bakshi, et al.	02/26/2002	
		2002/0137664	A1	Bakshi, et al.	09/26/2002	
		2002/0004512	A1	Bakshi, et al.	01/10/2002	
		2002/0143141	A1	Chen, et al.	10/03/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
			WO 00/74679		Bakshi, et al.	12/14/00		
			WO 01/05401		Dines, et al.	01/25/01		
			WO 00/53148		Stoner, Elizabeth	09/14/00		
Examiner Signature					Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\FORMS\PAT\1449a.pat.doc]

1. Unique citation designation number. 2. See attached Kinds of U.S. Patent Documents. 3. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN			
				Application Number		11/036,273	
				Filing Date		January 14, 2005	
				First Named Inventor		SHARMA, Shubh D.	
				Group Art Unit		1639	
				Examiner Name		Unknown	
Sheet	3	of	4	Attorney Docket Number		70025-US05-691	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No. ³	<u>U.S. Patent Document</u> Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
.		2003/0069169	A1	Macor, et al.	04/10/2003		
		2003/0083228	A1	Carpino, et al.	05/01/2003		
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	<u>Foreign Patent Document</u> Office ³ Number ⁴ Kind ⁵ Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
			WO 01/00224	Blood, et al.	01/04/01		
			WO 01/10842	Maguire, et al.	02/15/01		
			WO 02/18437	Chen, et al	03/07/2002		
			WO 99/36136	Wada, et al.	07/22/99		
Examiner Signature					Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\FORMS\PAT\1449a.pat.doc]

1. Unique citation designation number. 2. See attached Kinds of U.S. Patent Documents. 3. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10-31-99. OMB 0651-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				COMPLETE IF KNOWN			
				Application Number		11/036,273	
				Filing Date		January 14, 2005	
				First Named Inventor		SHARMA, Shubh D.	
				Group Art Unit		1639	
				Examiner Name		Unknown	
Sheet	4	of	4	Attorney Docket Number		70025-US05-691	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ⁴	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁵	
		Benelli A, Poggioli R, Luppi P, Ruini L, Bertolini A, Arletti R., (1994), oxytocin enhances, and oxytocin antagonism decreases, sexual receptivity in intact female rats, <i>Neuropeptides</i> : 27:245-50		
		Wessells H. et al., <i>J Urology</i> 160:389-393 (1998)		
		Van der Ploeg LH, et al., A role for the melanocortin 4 receptor in sexual function. <i>Proc Natl Acad Sci USA</i> . 99:11381-6 (2002)		
		Vergoni AV, et al. Chronic melanocortin 4 receptor blockage causes obesity without influencing sexual behavior in male rats. <i>J Endocrinol</i> , 166:419-26 (2000)		
		See generally <i>Synthetic Peptides: A User's Guide</i> , G.A. Grant, ed., W.H. Freeman & Co., New York (1992), the teachings of which are incorporated herein by reference, including the text and table set forth at pages 11 through 24		
		VJ, Al-obeidi F and Kazmierski W: <i>Biochem J</i> 268:249-262, 1990		
		Toniolo C: <i>Int J Peptide Protein Res</i> 35:287-300, 1990		
		M.E. Hadley et al., Discovery and development of the novel melanogenic drugs, in <i>Integration of Pharmaceutical Discovery and Development: Case Studies</i> , edited by Borschart et al., Plenum Press, New York (1998)		
		R.T. Dorr et al., Evaluation of Melanotan-II, A Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study. <i>Life Sci</i> . 58:1777-1784 (1996)		
		R.A.H. Adan, Identification of Antagonists for Melanocortin MC3, MC4, and MC5 Receptors. <i>Eur. J. Pharmacol.</i> , 269:331-337 (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[G:\FORMSPAT\1449b.pat.doc]

⁴ Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.